Group 1 - The core revenue of the company for the first half of 2025 reached 375 million yuan, with new orders amounting to 532 million yuan, reflecting a year-on-year increase of 7.39% [1] - The total backlog of orders stood at 1.112 billion yuan, which is a 14.29% increase compared to the end of 2024 [1] - The company experienced growth across all business segments, with a combined year-on-year increase of 6.86% in new projects for IND and NDA applications [1] Group 2 - The company is a leading comprehensive R&D service provider in the biopharmaceutical non-clinical research sector, recognized for its international service capabilities [2] - As of June 30, 2025, the company has successfully assisted in over 200 innovative drug research services, including several groundbreaking therapies and products [2] - The strategic project in Nantong has been successfully implemented, covering an area of 24,000 square meters and featuring 130 international standard animal housing units, which will enhance the company's capacity and efficiency in innovative molecules and advanced therapies [2]

从销售端来看，2025年公司各业务板块齐头并进，其中核心业务IND(新药临床试验申请)和NDA(新药上 市申请)的新签项目个数合计同比增长6.86%，彰显了公司强大的市场拓展能力。 2025年上半年，公司研发投入占营业收入的比例由上年的3.67%提升至5.94%，同比提升2.27个百分点。 在业绩承压的背景下，公司仍坚守稳定的研发投入规模，既体现了对技术创新的持续重视，也彰显了企 业务实创新的核心理念与对自身长期发展潜力的坚定信心。报告期内，公司新授权发明专利1项。截至 报告期末，公司拥有已授权的专利共计69项。 益诺思作为一家专业的提供生物医药非临床研究服务为主的综合研发服务(CRO)企业，是国内最早同时 具备NMPA的GLP认证、OECD的GLP认证、通过美国FDA的GLP检查的企业之一，与国际标准接轨， 具备了行业内具有竞争力的国际化服务能力，为全球的医药企业和科研机构提供全方位的符合国内国际 申报标准的一站式新药研发服务。 特别值得一提的是，公司海外布局成效显著，国际业务新签订单同比大幅增长，公司在国际市场上的认 可度和影响力逐步提升。其通过在核心业务领域的深耕细作与市场拓展策略的有效实施，在服务的客 ...